Fig. 5
From: The molecular basis of the anticancer effect of statins
Validation of the Synthetic Lethality hypothesis with Simvastatin. Half-maximal inhibitory concentration (IC50) is determined for different cancer cell lines, after 72 h of treatment with Simvastatin. (a) The MDA-MB-231 cell line, harboring a mutated KRAS gene that forms an SL pair with HMGCR, demonstrated an IC50 value of 2.108 µM, R2 = 0.9554. (b) The HCC1937 cell line, harboring a mutated BRCA1 gene that forms an SL pair with HDAC2, demonstrated an IC50 value of 20.94 µM, R2 = 0.8715. (c) The OVPA8 cell line, harboring a mutated BRCA1 gene that forms an SL pair with HDAC2, demonstrated an IC50 value of 8 µM, R2 = 0.8427. (d) The HeLa cell line, devoid of mutations that form SL pairs with the target genes of Simvastatin, remains unaffected across all tested Simvastatin concentrations.
